Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation

Journal of Neuroscience Research

Volumn 91, Issue 3, 2013, Pages 436-443

  Niespodziany, Isabelle ^a   Leclère, Nathalie ^a   Vandenplas, Catherine ^a   Foerch, Patrik ^a   Wolff, Christian ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drugs; Lacosamide; Slow inactivation; Voltage gated sodium channels

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; HARKOSERIDE; LAMOTRIGINE; PHENYTOIN; RUFINAMIDE; SPM 6953; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ANIMAL CELL; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; HYPERPOLARIZATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SODIUM CURRENT; STEADY STATE;

ACETAMIDES; ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; CELL LINE, TUMOR; MICE; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TIME FACTORS;

EID: 84872609965     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23136     Document Type: Article

References (34)

1. Arroyo S. 2007. Rufinamide. Neurotherapeutics 4: 155-162.
2. Biton V. 2007. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30: 230-240.
3. Biton V. 2012. Lacosamide for the treatment of partial-onset seizures. Expert Rev Neurother 12: 645-655.
4. Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. 2001. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 42: 600-608.
5. v1.1 channels and epilepsy. J Physiol 588: 1849-1859.
6. Errington A, Stöhr T, Heers C, Lees G. 2008. The investigational anticonvulsant Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73: 157-169.
7. Greenaway C, Ratnaraj N, Sander JW, Patsalos PN. 2011. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 52: 258-263.
8. Harris JA, Murphy JA. 2011. Lacosamide and epilepsy. CNS Neurosci Ther 17: 678-682.
9. Karolychyk MA, Schmidt D. 2002. Drugs in development. Rufinamide. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. Philadelphia: Lippincott-Raven. p 906-912.
10. Köhling R. 2002. Voltage-gated sodium channels in epilepsy. Epilepsia 43: 1278-1295.
11. Kuo CC, Bean BP. 1994. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol Pharmacol 46: 716-725.
12. + channels in rat hippocampal neurons. Br J Pharmacol 121: 1231-1238.
13. + currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol 51: 1077-1083.
14. Lang DG, Wang CM, Cooper BR. 1993. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 256: 829-835.
15. Liu G, Yarov-Yarovoy V, Nobbs M, Clare JJ, Scheuer T, Catterall WA. 2003. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 44: 413-422.
16. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. 2010. Voltage-gated sodium channels as therapeutics targets in epilepsy and other neurological disorders. Lancet 9: 413-424.
17. Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ. 1984. Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 228: 523-530.
18. McLean MJ, Schmutz M, Pozza MF, Wamil AW. 2005. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia 46(Suppl 8): 296.
19. + channels. J Membrane Biol 201: 1-8.
20. Quandt F. 1988. Modification of slow inactivation of single sodium channels by phenytoin in neuroblastoma cells. Mol Pharmacol 34: 557-565.
21. + currents in human dentate granule cells from epileptogenic tissue. Epilepsia 40: 401-407.
22. Rogawski M, Löscher W. 2004. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5: 553-564.
23. Rudy B. 1978. Slow inactivation of the sodium conductance in squid giant axons. Pronase resistance. J Physiol 283: 1-21.
24. Schauf CL. 1987. Zonisamide enhances slow inactivation in Myxicola. Brain Res 413: 185-188.
25. Sheets PL, Heers C, Stoehr T, Cummins TR. 2008. Differential block of sensory neuronal voltage gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine and carbamazepine. J Pharmacol Exp Ther 326: 89-99.
26. Stefan H, Feuerstein TJ. 2007. Novel anticonvulsant drugs. Pharmacol Ther 113: 165-183.
27. Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White HS. 2007. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74: 147-154.
28. Ulbricht W. 2005. Sodium channel inactivation: molecular determinants and modulation. Physiol Rev 85: 1271-1301.
29. Vassilev PM, Scheuer T, Catterall WA. 1988. Identification of an intracellular peptide segment involved in sodium channel inactivation. Science 241: 1658-1661.
30. v1.5 voltage-gated sodium channel subtypes using a membrane potential sensitive dye and FLIPR. Receptors Channels 10: 11-23.
31. Vilin YY, Ruben PC. 2001. Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. Cell Biochem Biophys 35: 171-190.
32. Wang Y, Park KD, Salome C, Wilson SM, Stables JP, Liu R, Khanna R, Kohn H. 2011. Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. ACS Chem Neurosci 2: 90-106.
33. Wasterlain CG, Stöhr T, Matagne A. 2010. The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus. Epilepsy Res 94: 10-17.
34. + channels in rat hippocampal neurons. Pflügers Arch 430: 437-446.